Amarin's drug Vascepa, a treatment for high triglyceride levels, was approved by the Food and Drug Administration this summer. While the company was able to successfully jump over this regulatory hurdle, it is currently trying to obtain New Chemical Entity, or NCE, status for its flagship drug. An NCE designation would give Vascepa five years of market exclusivity, while failure to obtain this status would result in only three years of protection. Fool.com health care bureau chief Brenton Flynn and analyst Max Macaluso discuss the potential impact of this decision on Amarin going forward.
Amarin has performed exceptionally well year to date -- but for every successful biotech stock, there are a plethora of failures. It's essential as an investor to diversify your portfolio with both speculative plays and more stable, long-term stocks. In our free report "3 Stocks That Will Help You Retire Rich," we reveal both stocks and strategies that can help you build wealth over the long term. Click here to get your copy today.
Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.